Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in metastatic pancreatic adenocarcinoma
2009-011305-17Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing ABI-007 plus gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: Overall survival. Started May 2011; status: terminated.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2009-011305-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011305-17.